Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Invested Capital (2016 - 2025)

Spero Therapeutics' Invested Capital history spans 10 years, with the latest figure at $59.0 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 27.96% year-over-year to $59.0 million; the TTM value through Dec 2025 reached $59.0 million, up 27.96%, while the annual FY2025 figure was $59.0 million, 27.96% up from the prior year.
  • Invested Capital reached $59.0 million in Q4 2025 per SPRO's latest filing, up from $26.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $118.8 million in Q1 2021 to a low of $26.5 million in Q3 2025.
  • Average Invested Capital over 5 years is $66.9 million, with a median of $64.2 million recorded in 2022.
  • Peak YoY movement for Invested Capital: tumbled 70.84% in 2022, then skyrocketed 64.61% in 2023.
  • A 5-year view of Invested Capital shows it stood at $88.3 million in 2021, then decreased by 13.99% to $75.9 million in 2022, then surged by 40.77% to $106.9 million in 2023, then plummeted by 56.85% to $46.1 million in 2024, then increased by 27.96% to $59.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Invested Capital are $59.0 million (Q4 2025), $26.5 million (Q3 2025), and $32.8 million (Q2 2025).